TRIPLE NEGATIVE BREAST CANCER
PATIENTS AND ONCOLOGISTS
HAVE A NEW ALLY
The BA100 Triple Negative Breast Cancer Stratification Test can identify which patients will not achieve complete response with the standard-of-care chemotherapy.
Until today, no stratification test existed for Triple Negative Breast Cancer Patients like there are for HER2+ and ER+ Breast Cancer. The lack of a stratification test meant that the vast majority of Patients received the standard-of-care chemotherapy with no indication of how they will respond. When has trial-and-error ever been a good strategy?
With the BA100 Triple Negative Breast Cancer Stratification Test, we not only know that roughly 67% of Triple Negative Breast Cancer Patients will not achieve a complete response to the standard-of-care chemotherapy, but we can identify who those patients are prior to treatment. Wouldn’t you like to know if your treatment will be effective beforehand?
HOW TO GET THE TEST
Since the BA100 test is new, we are still working on the data needed for insurance coverage. Because each case is unique, we are still learning how the stratification information will change treatment options for the roughly 67% of patients who we now know will not achieve a complete response to the standard-of-care chemotherapy. The good news is that incredible research is ongoing and new information and treatments are becoming available. For example, as of March 2018, there are over 150 recruiting clinical trials in the United States focusing on Triple Negative Breast Cancer. The Bioarray clinical advisors and BA100 early adopters will help us understand the new treatment options and standards.
Because of these things, the BA100 test is only available to selected Oncologists in the United States enrolling in a prospective clinical study. To learn how to enroll in the study, please contact us using the button below.